News/ News/ R&D Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trial Phil Taylor Catalyst Biosciences, gene therapy, Haematology, haemophilia, Novo Nordisk, Sangamo Therapeutics, Takeda, uniQure 0 Comment Catalyst Biosciences is a step closer to challenging Novo Nordisk’s NovoSeven in the haemophilia A and B market Share X Catalyst’s rival to NovoSeven hits the mark in phase 2 haemophilia trial https://pharmaphorum.com/news/catalysts-rival-to-novoseven-hits-the-mark-in-phase-2-haemophilia-trial/